Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 4,870 shares, a decline of 23.8% from the December 31st total of 6,390 shares. Based on an average trading volume of 17,808 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the company’s stock are short sold. Currently, 0.2% of the company’s stock are short sold. Based on an average trading volume of 17,808 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Sachetta LLC boosted its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,259 shares of the company’s stock after purchasing an additional 4,593 shares during the period. Sachetta LLC owned approximately 0.99% of Xenetic Biosciences worth $60,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.12% of the company’s stock.

Xenetic Biosciences Price Performance

Xenetic Biosciences stock opened at $2.22 on Friday. Xenetic Biosciences has a one year low of $1.90 and a one year high of $13.93. The business’s fifty day moving average is $2.33 and its 200 day moving average is $3.03. The stock has a market capitalization of $5.08 million, a PE ratio of -1.08 and a beta of 2.25.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Wednesday, November 12th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.16. The business had revenue of $1.03 million during the quarter. Xenetic Biosciences had a negative return on equity of 64.66% and a negative net margin of 110.42%. As a group, sell-side analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.